Mantle Cell Lymphoma Therapeutics Market Report 2026

Mantle Cell Lymphoma Therapeutics Market Overview

• Mantle Cell Lymphoma Therapeutics market size has reached to $2.6 billion in 2025 • Expected to grow to $3.81 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: The Surge In Mantle Cell Lymphoma Prevalence Driving Growth In Therapeutics Market • Market Trend: Product Innovations In The Mantle Cell Lymphoma Therapeutics Market • North America was the largest region in 2025.

What Is Covered Under Mantle Cell Lymphoma Therapeutics Market?

Mantle cell lymphoma therapeutics refers to treatment approaches and strategies used to manage mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma characterized by abnormal B-cell growth in the lymphatic system. These treatments use focused strategies like BTK and BCL2 inhibitors, which have long-lasting therapeutic effects. The main types of mantle cell lymphoma therapeutics are combination therapy and monotherapy. Combination therapy refers to the simultaneous use of multiple treatments or medications to enhance their effectiveness in treating a particular condition or disease, which is used in mantle cell lymphoma therapeutics to simultaneously use multiple treatment approaches, such as chemotherapy, targeted therapy, and immunotherapy, to optimize the treatment outcomes and improve patient outcomes. The drugs work by Bruton tyrosine kinase inhibitors, alkylating agents, deoxyribonucleic acid synthesis inhibitors, microtubule inhibitors, monoclonal antibodies, and others and are given by oral and parenteral routes. These are used by hospitals, research institutes, others.

What Is The Mantle Cell Lymphoma Therapeutics Market Growth Forecast?

The mantle cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.81 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to expansion of targeted and combination therapies, growth in oral BTK and BCL2 inhibitors, adoption of precision medicine approaches, increased investment in immunotherapy research, rising geriatric patient population. Major trends in the forecast period include targeted therapy expansion, immunotherapy advancements, oral therapeutics adoption, personalized medicine integration, combination therapy development.

Global Mantle Cell Lymphoma Therapeutics Market Segmentation

1) By Type: Combination Therapy, Monotherapy 2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors, Alkylating Agents, Deoxyribonucleic Acid Synthesis Inhibitors, Microtubule Inhibitors, Monoclonal Antibodies, Other Mechanisms 3) By Route of Administration: Oral, Parenteral 4) By Application: Hospital, Research Institute, Other Applications Subsegments: 1) By Combination Therapy: Chemotherapy Combinations, Targeted Therapy Combinations, Immunotherapy Combinations 2) By Monotherapy: Single-Agent Chemotherapy, Targeted Therapy Monotherapy, Immunotherapy Monotherapy

What Is The Driver Of The Mantle Cell Lymphoma Therapeutics Market?

The rise in the prevalence of mantle cell lymphoma is expected to propel the growth of the mantle cell lymphoma therapeutics market going forward. Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL), a cancer affecting the lymphatic system. Mantle Cell Lymphoma therapeutics help reduce the disease's prevalence by treating and managing the condition and improving patient outcomes, prolonged survival, and reduced disease burden. For instance, in February 2024, according to the Lymphoma Action, a UK-based charity dedicated to lymphoma, around 600 people in the UK are diagnosed with mantle cell lymphoma each year, a condition seen more often in men than women and typically identified in individuals who are middle-aged or older. Therefore, the rise in the prevalence of mantle cell lymphoma is driving the growth of the mantle cell lymphoma therapeutics industry.

Key Players In The Global Mantle Cell Lymphoma Therapeutics Market

Major companies operating in the mantle cell lymphoma therapeutics market are AstraZeneca plc, Celgene Corporation, Takeda Pharmaceutical Company Limited, Bayer Aktiengesellschaft, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Kite Pharma Inc., Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Juno Therapeutics Inc., Nurix Therapeutics Inc., Janssen Biotech Inc., TG Therapeutics Inc., F. Hoffmann-La Roche AG, Astellas Pharma Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Hutchison China MediTech Limited, Incyte Corporation

Global Mantle Cell Lymphoma Therapeutics Market Trends and Insights

Major companies operating in the mantle cell lymphoma therapeutics market are developing innovative products such as kinase inhibitors to meet larger customer bases, more sales, and increase revenue. A kinase inhibitor is a type of pharmaceutical agent that interferes with the activity of enzymes known as kinases. For instance, in January 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), indicated for adult patients experiencing a recurrence or resistance to prior treatments for mantle cell lymphoma (MCL). Jaypirca stands out as a highly selective kinase inhibitor, employing a unique binding mechanism. Distinguished by its ability to reestablish BTK inhibition in patients with mantle cell lymphoma (MCL) who have undergone prior treatment with covalent BTK inhibitors such as ibrutinib, acalabrutinib, or zanubrutinib, Jaypirca extends the advantages of targeting the BTK pathway.

What Are Latest Mergers And Acquisitions In The Mantle Cell Lymphoma Therapeutics Market?

In January 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired the development and commercialization rights to 2seventy bio’s preclinical and clinical cell-therapy pipeline for an undisclosed amount. Through this acquisition, Regeneron aims to expand its hematologic oncology capabilities by integrating next-generation cell-therapy programs and adding approximately 150 specialized employees to its newly established division, Regeneron Cell Medicines. 2seventy bio is a US-based cell-therapy company focused on developing therapies for hematologic malignancies, including B-cell lymphomas.

Regional Insights

North America was the largest region in the global mantle cell lymphoma therapeutics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Mantle Cell Lymphoma Therapeutics Market?

The mantle cell lymphoma therapeutics market includes revenues earned by entities by Brukinsa (zanubrutinib), Imbruvica (ibrutinib), Revlimid (lenalidomide), and Tecartus (brexucabtagene autoleucel). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mantle Cell Lymphoma Therapeutics Market Report 2026?

The mantle cell lymphoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mantle cell lymphoma therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.